A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
A phase 3 trial in which amrubicin is one of the standard comparator treatments, run by Daiichi Sankyo in small-cell lung cancer, now recruiting.
Overview
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06203210 by Daiichi Sankyo, with 540 participants planned, started 2024-05-21. Conditions listed: Small Cell Lung Cancer. Amrubicin is a comparator arm, not the drug under test. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Shares Amrubicin, Small-cell lung cancer.
- TrialA Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Shares Daiichi Sankyo, Small-cell lung cancer.
- TrialIfinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Shares Daiichi Sankyo, Small-cell lung cancer.
- TrialHERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Shares Daiichi Sankyo, Small-cell lung cancer.
- TrialStudy of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab
Shares Daiichi Sankyo, Small-cell lung cancer.
- TrialStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Shares Amrubicin, Small-cell lung cancer.
- TrialA Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-
Shares Daiichi Sankyo, Small-cell lung cancer.
- TrialStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Shares Daiichi Sankyo, Small-cell lung cancer.